Loading
Life sciences · Journal article
BMC Psychiatry · October 9, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
This study aimed to investigate the reversal of a high-risk metabolic syndrome (MetS) subtype (characterized by central obesity, hypertriglyceridemia, and low high-density lipoprotein cholesterol) following a switch from olanzapine (OLZ) to aripiprazole (ARI) in young patients with schizophrenia (SCZ). In this 6-month, prospective, single-arm study, 87 clinically stable patients with SCZ and the specified MetS subtype underwent a cross-titration from OLZ to ARI. 75 participants completed the protocol. Metabolic and psychiatric assessments were conducted at baseline and endpoint. Following the switch, significant reductions were observed in body weight ( p < 0.001), waist circumference ( p < 0.001), fasting blood glucose ( p = 0.002), and triglycerides ( p = 0.006). Psychiatric symptom severity remained stable ( p = 0.635), while the Global Assessment of Functioning score improved significantly ( p = 0.005) and treatment-emergent symptoms decreased ( p = 0.044). A total of 31 participants (41.33%) achieved a qualitative reversal of MetS diagnosis. Scheirer-Ray-Hare analysis revealed significant interaction effects between the intervention and metabolic diagnosis subgroups. Triglyceride levels decreased significantly in converters but paradoxically increased in non-converters (H = 19.42, p < 0.001), highlighting the heterogeneous metabolic response to this switching strategy. Switching from OLZ to ARI was associated with the reversal of a high-risk MetS subtype in a substantial proportion (41.33%) of patients without compromising psychiatric stability in this clinically pre-stabilized cohort. The marked heterogeneity in treatment response, however, indicates that this switch constitutes a foundational intervention. Early identification of patients less likely to respond is essential to guide adjunctive therapies for optimal cardiovascular risk reduction.